About this Research Topic
Colorectal cancer (CRC) remains a significant global health challenge, with a substantial impact on morbidity and mortality. Traditional treatments for CRC, including surgery, chemotherapy, and radiation therapy, have limited therapeutic efficacy. In recent years, the field of oncology has witnessed a paradigm shift towards precision therapy, driven by advances in genomics and molecular biology.
Precision therapy for CRC is based on the understanding that each patient's cancer is unique, with distinct genetic alterations driving tumor growth. This approach leverages comprehensive genomic profiling to identify specific mutations, gene expression patterns, and molecular signatures, allowing for the tailoring of therapies to individual patients. Targeted therapies, immunotherapies, and small molecule inhibitors have emerged as promising avenues for CRC treatment, offering improved response rates and reduced toxicity compared to conventional approaches.
This Research Topic aims to explore the latest breakthroughs, clinical trials, and therapeutic strategies in the realm of precision therapy for CRC, shedding light on the path toward more effective and personalized treatments for this challenging disease. We invite researchers to contribute their insights and findings to further advance our understanding and management of colorectal cancer.
We welcome Original Research articles, Reviews, and Clinical Studies that explore various aspects of precision medicine in the context of colorectal cancer. Topics of interest include but are not limited to:
-Molecular profiling and biomarker discovery
-Targeted therapies and immunotherapies
-Genomic and epigenetic alterations in CRC
-Patient stratification and personalized treatment strategies
-Clinical trials and therapeutic advancements
-Predictive modeling and drug response assessment
-Multidisciplinary approaches to precision therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Precision therapy for CRC is based on the understanding that each patient's cancer is unique, with distinct genetic alterations driving tumor growth. This approach leverages comprehensive genomic profiling to identify specific mutations, gene expression patterns, and molecular signatures, allowing for the tailoring of therapies to individual patients. Targeted therapies, immunotherapies, and small molecule inhibitors have emerged as promising avenues for CRC treatment, offering improved response rates and reduced toxicity compared to conventional approaches.
This Research Topic aims to explore the latest breakthroughs, clinical trials, and therapeutic strategies in the realm of precision therapy for CRC, shedding light on the path toward more effective and personalized treatments for this challenging disease. We invite researchers to contribute their insights and findings to further advance our understanding and management of colorectal cancer.
We welcome Original Research articles, Reviews, and Clinical Studies that explore various aspects of precision medicine in the context of colorectal cancer. Topics of interest include but are not limited to:
-Molecular profiling and biomarker discovery
-Targeted therapies and immunotherapies
-Genomic and epigenetic alterations in CRC
-Patient stratification and personalized treatment strategies
-Clinical trials and therapeutic advancements
-Predictive modeling and drug response assessment
-Multidisciplinary approaches to precision therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: dMMR/MSI-H, BRAF, KRAS, immunotherapy, gheckpoint inhibitor, ctDNA, genomic profiling
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
